Muhammad Ayub

Muhammad Ayub

Auto-generated profile, based on publicly available information

Muhammad Ayub

Department of Psychiatry, Queen’s University, Kingston, ON, Canada

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 February 2022 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
SFSegun Fatumo
Segun Fatumo
TCTinashe Chikowore
Tinashe Chikowore
ACAnanyo Choudhury
Ananyo Choudhury
MAMuhammad Ayub
Muhammad Ayub
AMAlicia R. Martin
Alicia R. Martin
KKKaroline Kuchenbaecker
Karoline Kuchenbaecker

15 December 2021 in Pharmacopsychiatry
Verified
Journal Article
Closed access
PDF file
JLJose de Leon
Jose de Leon
GSGeorgios Schoretsanitis
Georgios Schoretsanitis
RSRobert L. Smith
Robert L. Smith
EMEspen Molden
Espen Molden
ASAnssi Solismaa
Anssi Solismaa
DMDaniel Mueller
Daniel Mueller
This international guideline proposes improving clozapine package inserts worldwide by using ancestry-based dosing and titration. Adverse drug reaction (ADR) databases suggest that clozapine is the third most toxic drug in the United States (US), and it produces four times higher worldwide pneumonia mortality than that by agranulocytosis or myocarditis. For trough steady-state clozapine serum concentrations, the therapeutic reference range is narrow, from 350 to 600 ng/mL with the potential for toxicity and ADRs as concentrations increase. Clozapine is mainly metabolized by CYP1A2 (female non-smokers, the lowest dose; male smokers, the highest dose). Poor metabolizer status through phenotypic conversion is associated with co-prescription of inhibitors (including oral contraceptives and valproate), obesity, or inflammation with C-reactive protein (CRP) elevations. The Asian population (Pakistan to Japan) or the Americas’ original inhabitants have lower CYP1A2 activity and require lower clozapine doses to reach concentrations of 350 ng/mL. In the US, daily doses of 300–600 mg/day are recommended. Slow personalized titration may prevent early ADRs (including syncope, myocarditis, and pneumonia). This guideline defines six personalized titration schedules for inpatients: 1) ancestry from Asia or the original people from the Americas with lower metabolism (obesity or valproate) needing minimum therapeutic dosages of 75–150 mg/day, 2) ancestry from Asia or the original people from the Americas with average metabolism needing 175–300 mg/day, 3) European/Western Asian ancestry with lower metabolism (obesity or valproate) needing 100–200 mg/day, 4) European/Western Asian ancestry with average metabolism needing 250–400 mg/day, 5) in the US with ancestries other than from Asia or the original people from the Americas with lower clozapine metabolism (obesity or valproate) needing 150–300 mg/day, and 6) in the US with ancestries other than from Asia or the original people from the Americas with average clozapine metabolism needing 300–600 mg/day. Baseline and weekly CRP monitoring for at least four weeks is required to identify any inflammation, including inflammation secondary to clozapine rapid titration.

1 April 2008 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
ANAbdul Noor
Abdul Noor
CWChristian Windpassinger
Christian Windpassinger
MPMegha Patel
Megha Patel
BSBeata Stachowiak
Beata Stachowiak
AMAnna Mikhailov
Anna Mikhailov
MAMuhammad Ayub
Muhammad Ayub

8 April 2017 in BMC Psychiatry
Verified
Journal Article
Open access
PDF file
WLWeihui Li
Weihui Li
LZLi Zhang
Li Zhang
XLXuerong Luo
Xuerong Luo
BLBangshan Liu
Bangshan Liu
ZLZhipeng Liu
Zhipeng Liu
FNFarooq Naeem
Farooq Naeem
The evidence for effectiveness of Cognitive Behaviour Therapy (CBT) is robust and the national organizations in the United Kingdom and the United States recommend its use. It is not utilized to its full potential in low and middle-income countries. Adaptation of CBT treatment to the target culture may facilitate its uptake. This study explored views of patients with schizophrenia, their caregivers, and mental health professionals for the purpose of cultural adaptation of CBT. The project was conducted in a teaching hospital in China. Systematic content and question analysis were the techniques we used to analyse the data generated in a series of qualitative interviews (N 45) in China. After identification of emerging themes and categories we compared and contrasted the themes across different interviews recursively. Triangulation of themes and concepts was undertaken to compare further and contrast the data from the different participating groups. This work highlighted the barriers in therapy as well as opportunities for use of CBT in that environment. Patients and their carers in China use a bio-psycho-spiritual-social model of illness. CBT is not commonly used to help those with schizophrenia in China. This study will facilitate the therapists using CBT for people with psychosis in China. These results require to be tested in clinical trials.

25 June 2015 in BMC Medical Genetics
Verified
Journal Article
Open access
PDF file
MRMuhammad Arshad Rafiq
Muhammad Arshad Rafiq
CLClaire S Leblond
Claire S Leblond
ASArif Nadeem Saqib
Arif Nadeem Saqib
AVAkshita K. Vincent
Akshita K. Vincent
AAAmirthagowri Ambalavanan
Amirthagowri Ambalavanan
LXLan Xiong
Lan Xiong
Cohen Syndrome (COH1) is a rare autosomal recessive disorder, principally identified by ocular, neural and muscular deficits. We identified three large consanguineous Pakistani families with intellectual disability and in some cases with autistic traits. Clinical assessments were performed in order to allow comparison of clinical features with other VPS13B mutations. Homozygosity mapping followed by whole exome sequencing and Sanger sequencing strategies were used to identify disease-related mutations. We identified two novel homozygous deletion mutations in VPS13B, firstly a 1 bp deletion, NM_017890.4:c.6879delT; p.Phe2293Leufs*24, and secondly a deletion of exons 37-40, which co-segregate with affected status. In addition to COH1-related traits, autistic features were reported in a number of family members, contrasting with the “friendly” demeanour often associated with COH1. The c.6879delT mutation is present in two families from different regions of the country, but both from the Baloch sub-ethnic group, and with a shared haplotype, indicating a founder effect among the Baloch population. We suspect that the c.6879delT mutation may be a common cause of COH1 and similar phenotypes among the Baloch population. Additionally, most of the individuals with the c.6879delT mutation in these two families also present with autistic like traits, and suggests that this variant may lead to a distinct autistic-like COH1 subgroup.

8 June 2018 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
ZFZohreh Fattahi
Zohreh Fattahi
TSTaimoor I Sheikh
Taimoor I Sheikh
Luciana MusanteLuciana Musante
Luciana Musante
MRMemoona Rasheed
Memoona Rasheed
ITIbrahim Ihsan Taskiran
Ibrahim Ihsan Taskiran
HNHossein Najmabadi
Hossein Najmabadi
Exploring genes and pathways underlying intellectual disability (ID) provides insight into brain development and function, clarifying the complex puzzle of how cognition develops. As part of ongoing systematic studies to identify candidate ID genes, linkage analysis and next-generation sequencing revealed Zinc Finger and BTB Domain Containing 11 (ZBTB11) as a novel candidate ID gene. ZBTB11 encodes a little-studied transcription regulator, and the two identified missense variants in this study are predicted to disrupt canonical Zn2+-binding residues of its C2H2 zinc finger domain, leading to possible altered DNA binding. Using HEK293T cells transfected with wild-type and mutant GFP-ZBTB11 constructs, we found the ZBTB11 mutants being excluded from the nucleolus, where the wild-type recombinant protein is predominantly localized. Pathway analysis applied to ChIP-seq data deposited in the ENCODE database supports the localization of ZBTB11 in nucleoli, highlighting associated pathways such as ribosomal RNA synthesis, ribosomal assembly, RNA modification and stress sensing, and provides a direct link between subcellular ZBTB11 location and its function. Furthermore, given the report of prominent brain and spinal cord degeneration in a zebrafish Zbtb11 mutant, we investigated ZBTB11-ortholog knockdown in Drosophila melanogaster brain by targeting RNAi using the UAS/Gal4 system. The observed approximate reduction to a third of the mushroom body size—possibly through neuronal reduction or degeneration—may affect neuronal circuits in the brain that are required for adaptive behavior, specifying the role of this gene in the nervous system. In conclusion, we report two ID families segregating ZBTB11 biallelic mutations disrupting Zn2+-binding motifs and provide functional evidence linking ZBTB11 dysfunction to this phenotype.